The 'must attend' late phase drug development conference in America
Late Phase Drug Development World Americas will be one of the largest gatherings of pharmaceutical and biotech professionals in the United States
Late phase drug development is growing at around 20% annually, exceeding the growth rate of phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public safety concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency.
The content - key issues to be addressed include:
Strategic drivers
Regulatory environment
Registries and results databases
Enabling technologies in late stage development
Operational issues in late stage study management
Best practice case studies
Who will attend?
event sponsors
Premium sponsor:
Stream facilitator sponsor:
Breakfast seminar sponsor:
Presentation sponsor:
Exhibitor:
sponsorship opportunities
Do you want to do business with senior decision makers from the leading pharmaceutical and biotechnology companies and from the late phase industry?
Late Phase Drug Development World Americas is where you will meet your target market.
Dr Chris Allen
Dr Danica Marinac-Dabic
Dr Jens Rienhold
Beat Wilder
Dr Gilbert L’Italien
